Review

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Sudipta Pathak 1, Jacek R. Wilczyński 2 and Edyta Paradowska 1,*

1 Laboratory of Virology, Institute of Medical Biology of the Polish Academy of Sciences, 93-232 Lodz, Poland; spathak@cbm.pan.pl
2 Department of Surgical and Oncological Gynecology, Medical University of Lodz, 90-419 Lodz, Poland; jrwil@post.pl
* Correspondence: eparadowska@cbm.pan.pl; Tel.: +48-42-272-3638, Fax: +48-42-272-3630

Received: 15 December 2019; Accepted: 25 February 2020; Published: 29 February 2020

Abstract: Ovarian cancer (OC) is one of the leading causes of cancer death in women, with high-grade serous ovarian cancer (HGSOC) being the most lethal gynecologic malignancy among women. This high fatality rate is the result of diagnosis of a high number of new cases when cancer implants have already spread. The poor prognosis is due to our inadequate understanding of the molecular mechanisms preceding ovarian malignancy. Knowledge about the site of origination has been improved recently by the discovery of tube intraepithelial cancer (TIC), but the potential risk factors are still obscure. Due to high tumoral heterogeneity in OC, the establishment of early stage biomarkers is still underway. Microbial infection may induce or result in chronic inflammatory infection and in the pathogenesis of cancers. Microbiome research has shed light on the relationships between the host and microbiota, as well as the direct roles of host pathogens in cancer development, progression, and drug efficacy. While controversial, the detection of viruses within ovarian malignancies and fallopian tube tissues suggests that these pathogens may play a role in the development of OC. Genomic and proteomic approaches have enhanced the methods for identifying candidates in early screening. This article summarizes the existing knowledge related to the molecular mechanisms that lead to tumorigenesis in the ovary, as well as the viruses detected in OC cases and how they may elevate this process.

Keywords: ovarian cancer; human papilloma virus; cytomegalovirus; review

1. Introduction

Ovarian cancer (OC), the eighth most prevalent women’s cancer across the world, is a plethora of malignancies in the ovaries, fallopian tubes, and peritoneal cavity, which has been divided into two distinct types on the basis of histology, molecular pattern, and clinical outcomes. As per the GLOBOCAN study, 295,414 cases, 184,799 deaths, and 762,663 cases with 5-year survival were associated with ovarian cancer in 2018 [1]. Asian countries have the highest morbidity (51.6%) and mortality (49.9%) rates, while European countries hold the second highest morbidity (23.1%) and mortality (24.2%) rates [1]. Such poor survival rates result mostly from the fact that two-thirds of new cases are diagnosed at the FIGO stage III/IV, when cancer implants are already beyond the pelvis. Poor prognosis of this cancer type also owes to our inadequate understanding of the molecular mechanisms preceding ovarian malignancy. Ovarian cancer shares commonality in symptoms with gastrointestinal, genitourinary, and gynecological conditions, which restrains us from spotting signs specific to OC [2]. Asymptomatic early stages and failure in the identification of precursor lesions delay tumor detection, which hinders diagnosis at advanced stages (i.e., during primary peritoneal
The development of drug resistance and cancer relapse have limited the efficacy of the associated treatments, thus demanding identification of the markers that contribute to such events [4]. Although the early stages—for at least some of OC—seem to be identified as tubal intraepithelial carcinoma (TIC), precise knowledge about the initiation of TIC and its mechanisms of progression to invasive OC is still lacking. The majority of TICs are identified in the distal region of the fallopian tube (fimbria) that is exposed to the pelvic cavity. This suggests that carcinogenesis may be promoted or driven by several factors, including the tumor microenvironment (TME), pelvic inflammatory disorder (PID), hormonal and genetic changes. Potential risk factors can aid in identifying plausible targets for early phase detection. Advancements in genomic and proteomic approaches have improved methods for the identification of candidate biomarkers and helped to develop effective screening strategies for early detection [5]. Molecular profiling and individualized OC treatment have provided optimism regarding the role of individualized medicine for oncological patients [6].

Microbial infections are currently recognized as potent risk factors in some cancer types and are estimated to account for 15%–20% of all cancer cases [7]. According to the International Agency for Research on Cancer (IARC), six oncoviruses are involved in malignant cell transformation, including human papilloma virus (HPV), hepatitis B and C viruses (HBV and HCV), human T lymphotrophic virus type 1 (HTLV-1), Epstein–Barr virus (EBV), and Kaposi sarcoma herpesvirus (KSHV) [1]. Viruses can act as direct carcinogens, by infecting cells undergoing neoplastic transformation, or as indirect carcinogens, by causing chronic inflammation and immune suppression [8]. The human immunodeficiency virus type 1 (HIV-1) increases cancer risk indirectly, mostly through immune deficiency. Retroviruses carry oncogenes derived from cellular genes involved in mitogenic signaling and growth control, while DNA tumor viruses encode oncoproteins important for cell transformation [9]. Viruses have developed many strategies to evade recognition and the antiviral immune responses of the host. They may play the role of cofactors and potentiate the oncogenic effect of other pathogens. There is currently no evidence that viruses have the pathogenic capacity to give rise to ovarian cancer.

2. Ovarian Carcinogenesis

Ovarian tumors comprise a heterogeneous group of lesions, arising either from epithelial, germ cell, or sex-cord stromal tumors. Histologically, about 90% of ovarian tumors have occurred through the transformation of epithelial cells and are thus designated as epithelial ovarian cancer (EOC) [10]. There are four histological subtypes of EOC: serous, mucinous, clear-cell, and endometrioid. Low-grade and high-grade serous ovarian carcinomas (LGSO and HGSO, respectively) of the ovary are two different neoplasms, with distinct sites of origin, modes of carcinogenesis, and molecular–genetic features [11,12]. Approximately 10% of ovarian malignancies arise from germ cells, metastatic tumors, and unclassified tumors [10]. According to a dualistic model of ovarian carcinogenesis, EOC subtypes have been classified into two main categories: Type 1 neoplasms develop along a step-wise progression, from pre-malignant or borderline lesions, and display frequent oncogenic alterations in cellular signaling pathways, such as small GTPases (RAS), mitogen-activated protein kinases (MAPK), and the phosphoinositide-3-kinase-protein kinase (PI3K)-AKT. Type 1 tumors include: LGSO, seromucinous, endometrioid, clear cell carcinomas, mucinous carcinomas, and malignant Brenner tumors [13]. However, it has been proposed that cancers associated with endometriosis and mucinous OC be considered as a separate group [14]. Type 2 neoplasms are aggressive with poor prognosis and are characterized by mutations in tumor suppressor p53 protein (TP53) gene and genomic instability. It has been shown that p53 can induce DNA repair proteins during DNA damage, cell cycle arrest at the G1 phase, apoptosis, and senescence [13]. HGSO is a prototypical type 2 neoplasm, which is characterized by high-grade nuclear atypia with the potential for multinucleation. It was thought that HGSO originated from ovarian surface epithelial (OSE) cells [15]; however, evidence has suggested that HGSO originates from the distal end of the fallopian tube, ovary, or peritoneum [16–18]. Fallopian tube epithelium expressing TP53 mutation undergoes malignant transformation to serous tubal intraepithelial carcinoma (STIC) [19]. Over 90% of HGSO...
tumors have an alteration in TP53 gene [20]. A STIC may transform into a malignant tumor due to its location and metastasize to the ovary and pelvic peritoneum.

2.1. Ovulation

The main risk factors for HGSOC are the lifetime number of ovulations: the ovary can be confronted with carcinogenesis if the number of lifetime ovulations correlates with an increased risk of OC [21]. Ovulation promotes the migration and adhesion of malignant cells to the ovary by disrupting the OSE, as well as releasing chemokines and cytokines [22]. The wound thus formed is repaired by the proliferation of the epithelial cells and such aggregation forms inclusion cysts, which have the potential to trigger ovarian carcinogenesis [15,18,23,24]. During ovulation, the malignant transformation of cortical inclusion cysts (CICs) in the ovarian cortex has been hypothesized to play a role in the progression of HGSOC. Recent studies have revealed that HGSOC arises from occult carcinomas in the fallopian tube, while a subset of HGSOC may develop from CICs derived from the implantation of the tubal epithelium when the OSE is disrupted at ovulation [25]. This is of clinical relevance, since HGSOC displays a morphology similar to serous carcinomas arising in the female genital tract encompassing the presence of papillary or glandular structures and cytologic atypia [26]. Epidemiological data have shown that estrogen—which, under normal conditions, regulates the function of OSE—has an influence on the progression of OC [27]. Syed et al. [28] showed that estrogen poses a paradoxical role in the expression of tumor suppressor genes and oncogenes. Within normal OSE, estrogen is known to promote cellular growth in a non-oncogenic direction and repair of follicular ruptures. However, within malignant OSE, it begins to support the course of ovarian carcinogenesis by decreasing the expression of genes associated with the stable growth of cells and enhancing the expression of genes associated with oncogenic potential [28]. Regulatory hormones and growth factors which display dichotomous functions in the ovary have provided effective targets for hormone therapies and growth blockers in ovarian cancer treatment [29,30].

2.2. Inflammation

Inflammation is an important factor in promoting ovarian cancer cell proliferation and metastasis. Ovulation, PID, endometriosis, polycystic ovarian syndrome, and obesity are major sources of inflammation in ovarian and fallopian tube tissues [31,32]. In vivo stimulation of ovulatory wound repair, ovulation, and ovarian surface scarring increases the seeding of cancer cells and infiltration of immune cells at the wound site and tissues surrounding the ovary. Inflammatory events during ovulation and ovulatory wound repair contribute to an increased risk of OC [33].

Chronic inflammation in the peritoneum results in the activation of signaling pathways, and immune responses, thus emerging as an important risk factor for EOC. It potentiates the transformation of cells from normal to malignant in fallopian tube and ovary. Data have supported that the overexpression of inflammatory pathways promotes EOC tumorigenesis, and resistance to chemotherapy. Several factors, such as interleukins (e.g., IL-1, IL-6, IL-8), tumor necrosis factor type α (TNF-α), and others are produced by tumor cells and activated by immune cells in tumor milieu [34–36]. The activation of the innate immune response employs macrophages and dendritic cells (DCs) to secrete chemoattractants, including IL-8 and monocyte chemotactic protein-1 (MCP-1) and usher the recruitment of neutrophils, lymphocytes, and natural killer (NK) cells, which produce reactive oxygen species (ROS), cytokines, chemokines, and growth factors [32]. High oxidative stress results in oxidative damage, which increases the expression of molecular drivers of mutagenesis, such as activation-induced cytidine deaminase (AID). AID subsequently introduces DNA damage, genomic rearrangements, and global hypomethylation, which contribute to the malignant transformation of OC [37]. The interaction of cytokines with Toll-like receptors (TLRs) at the tumor cell surface initiates the activation of proinflammatory pathways, mediated by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and the signal transducer and activator of transcription (STAT) [32]. The infiltration of tumor-associated macrophages (TAMs) into the TME is mediated by MCP-1 and colony-stimulating factor 1 (CSF-1). At the site of inflammation, the polarity of TAMs shifts to M1 phenotype through their interaction with interferon-γ (IFN-γ), TNF-α and TLR-
mediated interaction with endotoxins (lipopolysaccharides, LPS), whereas M2 macrophages are stimulated by IL-4/IL-13, IL-10, and transforming growth factor-beta (TGF-β) [38,39]. M2 macrophages release immunosuppressive cytokines (IL10, TGF-β) which contribute to OC tumor progression [38]. High expression of programmed death ligand-1 (PD-L1) on M2 macrophages and the production of immune inhibitory molecules B7-H4 repress the adaptive immune response, inactivate the cytotoxic T-cell response, and are associated with advancement in OC tumor stage [40,41].

Pattern recognition receptors (PRRs), such as TLRs, primarily play a role in activating antigen-presenting cells (APCs) to stimulate cytotoxic responses, maintaining tissue repair at the ovulation site [42]. Conversely, tumorigenesis in OC is facilitated by the interaction of TLRs on tumor cells with different effector molecules: a) TLR5 with MyD88 [43]; and b) TLR9 with unmethylated CpG DNA motifs released from surrounding necrotic cells [44]. OSE expresses TLRs receptive to microbial pathogen-associated molecular patterns (PAMPs) in order to facilitate protection against common gynecological infections. However, the resilient infection exhibited by oncolytic pathogens holds the potential to downregulate the expression of and subdue the inhibitory pathways mediated by TLRs [45,46]. Zhou et al. revealed that the transcriptional profiles of genes involved in TLR and NOD-like receptors (NLR) signaling pathways were different between OC tissues and normal distal fallopian tubes [47].

In TME of HGSOC tumors, the collagen fibers allow CD8+ T-cells to cross the stromal barrier and engage with major histocompatibility complex (MHC) class I molecules on the epithelial cancer cells [48]. CD8+ T-cells cooperate with CD20+ B-cells to promote antitumor immunity, possibly by inhibiting the development of T-cell anergy [49]. The accumulation of regulatory T cells (Tregs) in TME, probably induced by an inflammatory stimuli, may lead to significant immune suppression in the advanced stages of OC [50]. Release of IL-10 and TGF-β from Treg inhibits cytotoxic functions of T-cells via direct contact. Moreover, B7-H4+ overexpression on the OC cells and tumor-associated macrophages increase the ratio of Tregs/CD8+ T cells and associate with poor prognosis [51]. High Treg/T helper 17 (Th17) ratio promotes EOC progression and metastasis into the peritoneum [52]. Adoptive T-cell therapy for the conversion of Treg to proinflammatory Th17 and genetically modifying APCs with co-stimulatory ligand may enhance cytotoxic effects of T cells [53].

3. Microbiome in Ovarian Cancer

The infectious nature of carcinogenic pathogens distinguishes them from other cancer-causing factors. In vitro models have demonstrated the carcinogenic potential of common bacterial (Chlamydia trachomatis, Mycoplasma genitalium) and viral (HPV) pathogens in the infection of female reproductive organs and PID [54]. There is currently no evidence to support the hypothesis that microorganisms have the capacity to give rise to OC. However, the increased risk of ovarian carcinogenesis in the fallopian tubes and PID may raise concerns about the involvement of pathogens in OC. Persistent infections induce chronic inflammation, angiogenesis, and immune response as a part of ovarian tumor pathogenesis. The ovaries and their neighboring parts in the female genitalia are highly susceptible to infection from outside pathogens via the peritoneal tract. In addition, chronic inflammation, a low count of APC, and anti-apoptotic capacity during the reparation of the epithelial surface cause the epithelial cells to be more susceptible to infection [55]. The upper reproductive tract is not sterile and has a unique microbiome which has received increased attention [47,56].

Profiling the microbiome composition has provided insights into the viruses in ovarian tumors [56]. It has shown signatures of Retroviridae, followed by Hepadnaviridae, Papillomaviridae, Flaviviridae, Polyomaviridae and Herpesviridae (human cytomegalovirus—CMV, EBV, KSHV, and HHV6) families [56]. Approximately 23% of these were identified as tumorigenic viruses and were prevalent in more than 50% of screened cancer samples. However, the heterogeneity of the microbiome in the ovary has posed a challenge; for example, in latent infections, as well as the differential pattern of microbial existence in ovarian tumors and surrounding ovarian tissues in the same patient [56]. It seems possible that immunosuppression in the local microenvironment of the tumor creates a milieu favorable to the persistence of specific viruses. During the two last decades, with the use of highly
sensitive techniques, several groups have detected the presence of some viruses in OC cases. It should be noted that the detection of a viral genome in OC tissues is not sufficient to prove viruses as a causal factor in the genesis of disease. Viral sequences have been commonly detected in both non-malignant and malignant ovarian tissues. Moreover, there has been a lack of suitable animal model systems which mimic the progression of this human disease. Moreover, viruses detected in tumors from OC patients are strictly species-specific and cannot be propagated in vitro (i.e., HPV), which delays the development of in vivo models for viral infections. In Table 1, we present studies that have searched for viral infections in OC tissues, benign ovarian tumors, and tissues surrounding such tumors.

### Table 1. Virus detection in ovarian cancer.

| Histology of Tumors | Prevalence; n (%) | Virus | Detection Method | Reference | Year |
|---------------------|-------------------|-------|------------------|-----------|------|
| Epithelial ovarian adenocarcinoma | 0/18 (0) | HPV6, 16, 18, 31, 35 | Southern hybridization | Leake, J. F.; et al. [57] | 1989 |
| Epithelial ovarian tumor of low malignant potential | | HPV6, 11 | PCR | | |
| Epithelial ovarian adenoma | | | | |
| Serous OC | 1/7 (14.28) | HPV16, 18 | PCR (E6 gene), Southern hybridization | Lai, C. H.; et al. [58] | 1992 |
| Mucinous OC | 1/3 (33.3) | HPV16 | PCR (E6 gene), Southern hybridization | Runnebaum, I. B.; et al. [59] | 1995 |
| Mixed (serous+mucinous OC) | 1/1 (100) | HPV18 | | | |
| Serous, Endometrioid, Mixed Undifferentiated, Clear cell, Malignant mixed Mullerian tumor with heterologous elements | 0/28 | HPV16, 18 | PCR (L1 and E6 genes), dot blot | Runnebaum, I. B.; et al. [59] | 1995 |
| Serous, Mucinous, Endometrioid, Clear cell, Brenner, Mixed epithelial, Unclassified epithelial | 0/98 | LR-HPV types (6, 11, 42, 44, 51, 53, 54, 55, 67, 68, 70) and HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, 58, 66) | PCR (L1 gene), ISH | Anttila, M.; et al. [60] | 1999 |
| EOC | 26/50 (52) | HPV16 | ISH (E6 gene), IHC (E6) | Wu, Q. J.; et al. [61] | 2003 |
| Malignant ovarian tumor | 15/40 (37.5) | Not specified | ISH, IHC | Kuscu, E.; et al. [62] | 2005 |
| Benign ovarian tumor | 9/32 (28.1) | Not specified | PCR (L1 gene); DNA sequencing | Atalay, F.; et al. [63] | 2007 |
| Serous cystadenocarcinoma | 8/76 (10.5) | HPV16, 33 | PCR (L1 gene); DNA sequencing | Giordano, G.; et al. [64] | 2008 |
| Epithelial ovarian neoplasms | 3/71 (4.2) | Not specified | PCR (L1 gene); DNA sequencing | Malisic, E.; et al. [66] | 2012 |
| Serous adenocarcinoma | 3/12 (25) | | | | |
| Mucinous adenocarcinoma | 0/6 (0) | HPV6 | Nested PCR (E6and E7 genes) | Shanmugapriya, S.; et al. [65] | 2012 |
| Endometrioid adenocarcinoma | 3/6 (50) | HPV6 | Nested PCR (E6and E7 genes) | | |
| Borderline serous OC | 6/6 (100) | | | | |
| Serous OC | 2/35 (5.7) | HPV16 | PCR (L1 gene); DNA sequencing | Malisic, E.; et al. [66] | 2012 |
| Mucinous OC | 1/2 (50) | HPV16 | PCR (L1 gene); DNA sequencing | Malisic, E.; et al. [66] | 2012 |
| Endometrioid carcinoma | 1/7 (14.28) | HPV16, 18, 45 | | | |
| Ovarian carcinoma | 42/100 (42) | | | | |
| Non-cancerous tissue surrounding tumor                                                                 | 8/100 (8) | HPV6, 11 | Nested PCR (L1 gene; DNA sequencing) | Al-Shabanah, O. A.; et al. [67] |
|--------------------------------------------------------------------------------------------------------|-----------|----------|-------------------------------------|---------------------------------|
| EOC                                                                                                    | 2/20 (10) | HPV16    | PCR (E6 gene)                       | Bilyk, O. O.; et al. [68]       |
| Serous, Endometrioid, Mucinous, Clear-cell                                                            | 4/20 (20) | HPV16/18 | qRT-PCR (E6/E7 genes)               | Ingerslev, K.; et al. [69]       |
| EOC                                                                                                    | 5/100 (5) | HPV16    | Nested PCR (L1 gene); DNA sequencing | Hassan, Z. K.; et al. [70]       |
| EOC                                                                                                    | 4/100 (4) | HPV18    |                                     |                                 |
|                                                                                                       | 1/100 (1) | HPV33    |                                     |                                 |
| EOC                                                                                                    | 40/99 (40.4) | HPV2, 4, 5, 6b, 7, 10, 16, 18, 32, 48, 49, 50, 60, 54, 92, 96, 101, 128, 129, 131, 132 | Microarray-based method, PathoChip Array | Banerjee, S.; et al. [56]       |
| Non-cancerous tissue surrounding tumor                                                                 | 20/20 (100) | HPV41, 88, 53, 103 |                                     |                                 |
| EOC                                                                                                    | 19/27 (70.4) | HPV16    | Nested PCR (E6 gene); DNA sequencing | Paradowska, E.; et al. [71]       |
| Metastatic ovarian tumors                                                                               | 2/27 (7.4) | HPV6     |                                     |                                 |
| Benign ovarian tumors                                                                                   | 1/27 (3.7) | HPV45    |                                     |                                 |
| Serous adenocarcinoma                                                                                   | 4/4 (100) | HPV16    |                                     |                                 |
| Serous adenocarcinoma                                                                                   | 2/8 (25)  | HPV16    |                                     |                                 |
| Mucinous adenocarcinoma                                                                                 | 6/12 (50) | CMV      | Nested PCR (UL55 gene)              | Shanmughapriya, S.; et al. [65] |
| Endometrioid adenocarcinoma                                                                            | 3/6 (50)  | CMV      |                                     |                                 |
| Borderline serous OC                                                                                   | 3/6 (50)  | CMV      |                                     |                                 |
| Serous adenocarcinoma and other histotypes                                                             | 34/45 (75.5) | CMV (IE) | IHC (IE and pp65)                  | Rådestad et al. [72]            |
| Benign ovarian cystadenoma                                                                             | 11/42 (26.2) | CMV (pp65) |                                     |                                 |
| HGSOC with prechemotherapy                                                                             | 20/30 (67) | CMV (IE) |                                     |                                 |
| HGSOC with neoadjuvant chemotherapy                                                                    | 4/29 (14) | CMV (pp65) |                                     |                                 |
| EOC                                                                                                    | 8/10 (80) | CMV (IE) |                                     |                                 |
| Metastatic ovarian tumors                                                                               | 4/10 (40) | CMV (pp65) |                                     |                                 |
| Benign ovarian tumors                                                                                   | 3/3 (100) | CMV (DNA) |                                     |                                 |
| HGSOC with neoadjuvant chemotherapy                                                                    | 4/9 (44)  | CMV (IE) | IHC (IE and pp65), ISH (DNA 82.7)   | Carlson et al. [73]             |
| Serous, mucinous, and endometrioid adenocarcinomas, clear-cell carcinomas                              | 5/5 (100) | CMV (DNA) |                                     |                                 |
| EOC                                                                                                    | 19/27 (70.4) | CMV      | Nested-PCR (US28 gene), DNA sequencing | Paradowska, E.; et al. [71]       |
| Metastatic ovarian tumors                                                                               | 4/4 (100) | CMV      |                                     |                                 |
| Serous, mucinous, and endometrioid adenocarcinomas, clear-cell carcinomas                              | 0/8 (0)   | CMV      |                                     |                                 |
| Ovarian serous cystadenocarcinoma                                                                       | 1/191 (0.5) | CMV      | qRT-PCR, DNA sequencing              | Ingerslev, K.; et al. [74]       |
| Ovarian serous cystadenocarcinoma                                                                       | 0/419 (0) | EBV      | RNA-Seq                             | Khoury, J.; et al. [75]          |
| Serous OC                                                                                                | 38/487 (7.8) | EBV      | miRNA expression, qRT-PCR           | Pandya, D.; et al. [76]          |
| EOC                                                                                                    | 0/27 (0)  | EBV      | qRT-PCR, nested PCR                | Paradowska, E.; et al. [71]       |
| Serous, mucinous, and endometrioid                                                                       | 10/191 (5.2) | EBV      | qRT-PCR, DNA sequencing, ISH        | Ingerslev, K.; et al. [74]       |
HPV is one of the most common types of sexually transmitted virus in the world. In the United States, the prevalence of oral HPV among adults has been reported as 7.3%, while genital HPV prevalence was 42.5% [77]. The HR-HPV prevalence in China was 17.7% [78]. Tang et al. detected HPV in 96.6% of cervical, and 14.1% of head and neck, bladder urethelial, and lung squamous cell carcinomas [79]. Hitherto, the prevalence of HPV in the pathogenesis of OC is still controversial. Some reports have confirmed the presence of HPV in malignant ovarian cancer [56,58,61–68,70–73], while others did not [57,59,60] (Table 1). Differences in detection methods, low copy number of HPV DNA, sample types, small sample size, and geographic regions of sample origin were potential causes of such discrepancies. Studies from Asia have generally reported a higher prevalence of HPV in EOC tumor tissues than studies from Western countries [80,81]. Overall, the HPV prevalence in patients with OC was found as 17.5% [81]. High-risk HPV16 and HPV18 are predominant genotypes associated with advanced stages of OC [61,66–68]. Molecular signatures of high-risk HPV (HR-HPV) types, along with low-risk HPV (LR-HPV) types, mostly HPV6, were detected in OC samples, while LR genotypes were found in non-cancerous controls [71]. Banerjee et al. [56] found widespread integration of HPV sequences into the genome of tumor cells. Integration of HPV E6 and E7 oncogenes has been shown to trigger the degradation of tumor suppressing proteins (p53 and Rb) and induce tumorigenesis [82,83].

Hidden herpesviruses may play an important role in the ovarian environment. However, the correlation between herpesviruses and OC remains controversial. CMV is not a typical oncogenic virus, but it is known for its characteristic of oncomodulation to enhance tumor growth and migration [84,85]. Approximately 50% of ovarian cancers in the Indian population have been shown to be positive for CMV DNA, of which 80% were invasive and 20% were borderline tumors [65]. In contrast, no association was observed between CMV and OC in the Danish population [74]. It was suggested that tumor heterogeneity, the uneven distribution of infected cells, and differences in the methodological approaches might be a probable reason for no prevalence of CMV in ovarian tumor tissues despite involving a large sample-size study. Higher prevalence of EBV DNA was noted in patients with EOC, as compared to a benign control group [74]. The incongruent findings in the microbiome in OC could be due to the possibility that the involved pathogen was not present at the time point at which OC was diagnosed [86]. After the virus alters the gene expression pattern and heritable changes are triggered in the host cell, recurrent DNA recombinogenic activities occur that may lead to the loss of the viral genome from cells during neoplastic transformation. With respect to this speculation, methods that entail the study of “hit and run” oncogenic effects of the pathogen could be strategized for efficient detection [86].

Some studies have suggested the association of bacteria, including Chlamydia, Mycoplasma and Brucella, with OC [64,70,87]. Bacterial pathogens develop chronic, asymptomatic infections and enhance the risk of OSE neoplastic transformation. Chlamydia trachomatis is an obligate intracellular bacterium which causes an asymptomatic infection by preventing phagosome–lysosome fusion, evading the host’s immune response, degrading transcriptional factors, and impeding the expression of MHC and cytokines [88,89]. The mechanisms involved in bacterial infection, such as the inhibition of DNA damage repair proteins [84], degradation of p53 [90], and cell cycle disruption due to increased MAPK signaling [89], ensure the survival of the bacterium while fostering a predisposition to carcinogenesis [91]. C. trachomatis DNA was detected in 80% of OC samples [65]. Mycoplasma genitalium has been detected in pelvic inflammation and tubal factor infertility [92]. Chlamydia and Mycoplasma have also been found in at least 60% of screened OC samples [56,65,93]. Neisseria gonorrhoea causes genital infections such as cervicitis/urethritis and pelvic inflammation and triggers DNA
damage, downregulation in p53 expression, and arrest at G1 phase in the cell cycle [94]. However, a study carried out by Idahl et al. [95] showed no association of M. genitalium or N. gonorrhoea with OC.

4. The Role of Human Papillomavirus in Oncogenesis

HPV is a small, non-enveloped, DNA virus with a single double-stranded genome. Over 200 types of HPV have been identified. LR-HPV types, including HPV6 and HPV11, cause the formation of benign lesions (i.e., genital warts), but rarely give rise to cervical cancers. High oncogenic potential HPVs include mainly HPV16, 18, 31 and 45, and these types cause intraepithelial neoplasia (or flat warts), which advance to invasive cancers [96,97]. Among them, HPV16 most likely causes cervical, vaginal, vulvar, penile, and anal cancers, as well as cancers of the head and neck [97]. The role of HPV in the predisposition of cancer has not been restricted to these cancers but also in colon, lung, and breast cancers. Cancers with HPV-positive infection exhibit a distinctive etiology, carcinogenesis, and tumor biology (i.e., lower DNA content, smaller cell nuclei, basaloïd growth of lesions), providing further challenges for detection [98]. In most cases, HPV infection resolves spontaneously, while in rare cases, the infection persists for several years. Productive infection generates as much as 100 copies of the viral genome in every cell, where viral genomes are maintained as episomes and amplified in daughter cells. If the infection is caused by an HR-HPV type, the infection can persist, leading to genomic instability and neoplastic transformation of the epithelium.

The early region of HPV genomes encodes six proteins (E1, E2, E4–E7) necessary for viral replication, while the late region encodes two structural proteins (L1 and L2) which are required for virion assembly and transmission [96,99,100]. E6 and E7 act as oncogenes that promote tumor growth and malignant transformation, targeting several negative regulators of the cell cycle, including p53 and retinoblastoma protein (pRB), respectively. HPV takes the opportunity at the division of the epithelium, anchoring to surface molecules (heparin sulphate proteoglycans) on the basal epithelium to pave its way inside the cell by clathrin-mediated endocytosis; finally, the viral DNA inhabits the host cell nucleus in its episomal form [99,101]. Breakdown of the nuclear envelope and binding of L2 protein with dynein are required for the transport of HPV DNA to the nucleus [102,103]. E1 and E2 are expressed to maintain low expression levels of the E6 and E7 oncoproteins to avoid activation of tumor progression [99,101]. This thus raises the possibility for effective early-stage detection of HPV by targeting early proteins such as E1 and E2 when oncoproteins like E6 and E7 are expressed at low levels [104]. The HR-HPV E6 oncoprotein promotes proteosomal degradation of p53, eliminates the trophic sentinel response for viral DNA synthesis and upregulates telomerase activity to evade cell senescence [105–107]. E7 inactivates pRB to override p21-mediated growth arrest and upregulates p16 for the immortalization of cells [105,107]. E6 eliminates the “trophic sentinel” response, a defense mechanism against the replication of viral DNA induced in absence of a mitogen that helps in the synthesis of viral DNA and evasion of cell senescence [100]. The upregulation of telomerase activity by E6 in concert with the upregulation of p16 activity by E7 leads to escape from cell-death and the immortalization of epithelial cells [106]. E6 and E7 are required for maintaining malignant transformation while other viral proteins (e.g., E5) contribute to neoplastic proliferation in the early stages of viral infection. The persistence of HPV infection may last several years, which puts the host in danger of tumor progression [108].

Upon integration of HPV DNA into the host genome, E5 complexes with epidermal growth factor receptor (EGFR) to induce EGF-dependent activation of the mTOR pathway and EGF-independent activation of signaling cascades of MAP kinase p38 (regulating the expression of E6 and E7 genes in HPV16 infected cells) [109] and Erk1/2 pathway (for proliferation) [109–112] (Figure 1). E5 stimulates overexpression of c-Jun, junB, and c-fos through AP-1 and NF-1, thus transactivating the viral genes E6 and E7. The cellular transformation is further augmented by suppression of p21, complementing suppression of pRB by E7. E5 expression is coupled with the dephosphorylation of Connexin 43, as well as E5-stimulated c-Jun and junB expression, impairing cell–cell contact and anchorage-dependent growth, one of the early characteristics of cancer cells [110]. The unique characteristics of viral transcription are the initiation of transcription at more than one promoter site and polycistronic pre-mRNA, causing the expression of multiple RNAs with many open reading
frames. In addition to this event, the splicing mechanism maintains the proteomic diversity and generates isoforms of viral proteins E2 [113] and E6 [114]. The isoform of E6, E6*I, is considered to have anti-tumorigenic effects—it abrogates E6-mediated p53 degradation and help in initiating apoptosis [115]. E6*I has an antagonizing effect on E6 function and may alleviate the virulence of HPV in the infected cells. However, other effects of E6*I, such as the promotion of DNA damage and stabilization of E6 and E7, are involved in cancer development [116,117].

Figure 1. Signaling pathways deregulated in the presence of high-risk HPV. High-risk HPV infection increases cancer risk by: a) Increasing cell proliferation (PI3K/AKT mTOR, Ras-ERK, β-catenin pathways); b) Increasing cell proliferation and progression by the inactivation of p53 expression, E-cadherin and hypermethylation of tumor suppressor genes; c) Increasing immortalization of cancer cells by increasing telomerase activity and AURKA at G2/M phase; d) Increasing intercellular communication and epithelial-mesenchymal transition by upregulating the expression of oncomirs and inhibiting the interaction of histone proteins with ubiquitin ligases. Abbreviations: phosphoinositide 3-kinases (PI3K), serine/threonine-protein kinase (AKT), mammalian target of rapamycin (mTOR), epidermal growth factor (EGF), GTPase Ras (Ras), serine/threonine-protein kinase B-raf (BRAF), mitogen-activated protein kinases (MEK and ERK), chemokine (C-X-C motif) ligand 1 (CXCL1), telomerase reverse transcriptase (hTERT), aurora kinase A (AURKA), cell adhesion
molecule 1 (CADM1), myelin and lymphocyte protein (MAL), paired box 1 (PAX1), adenylate cyclase activating polypeptide 1 (ADCYAP1), secreted frizzled-related protein (SFRP) and adenomatous polyposis coli (APC), NF-κB-inducing kinase (NIK), and TRAF-interacting protein (TIP).

A meta-analysis on the prevalence of HPV in OC showed 15.5% (0%–67%) HPV-positive OC cases worldwide [80]. The presence of HR-HPV genotypes in not just the lower, but also upper genital tract can suggest that HPV may be involved in the development of EOC [68,71]. HR-HPV E6 and E7 have been found to be expressed in ovarian tumors [118]. Infection with HR-HPV renders low expression of p53 and high expression of p16 in OC; furthermore, the expression of E6 has been shown to be suggestive of low expression of p53 [119]. The integration of the HPV genome into the host genome leads to cell cycle disruption and increased genetic instability in the host (Figure 1). Arfi et al. found the same locus and the same nucleotide breaks for HPV18 DNA integration with high expression of p16, which is indicative of ovarian metastasis from cervical adenocarcinoma [120]. Examining the locus of viral–host integration will be beneficial to study the role of HPV in ovarian tumors for patients with a history of HPV-positive cervical cancer.

In cervical cancer, HPV DNA integration in the host genome, genomic rearrangement, involving structural changes at the HPV DNA integration site, and the activation of replication at viral integrated sequences contribute to oncogenesis [121–123]. Genetic alterations which foster carcinogenesis involve DNA methylation and nucleotide polymorphisms. HPV-mediated promoter hypermethylation of tumor-suppressor genes, such as cell adhesion molecule 1 (CADM1), myelin and lymphocyte protein (MAL), paired box 1 (PAX1), adenylate cyclase activating polypeptide 1 (ADCYAP1), secreted frizzled-related protein (SFRP) and adenomatous polyposis coli, may have implications in the development of OC [71,121].

The activation of the PI3K/AKT/mTOR signaling pathway may play a key role in the virus–host interaction in HPV-positive cancer cells. HPV not only integrates within the host genome, but strongly associates with the host’s biochemical cascades to steer carcinogenesis. HPV proteins drive carcinogenesis quite contrarily—while E7 enhances the Wnt/β-catenin signaling pathway and yes-associated protein 1 (YAP1) expression, E2 suppresses E7 expression and makes β-catenin and its coactivators less available. It was shown that E1 induced the transcription of antioxidant response elements (ARE), increased the expression of cytoprotective genes, and pushed cancer cells towards chemoresistance. The invasiveness of cancer cells and epithelial-mesenchymal-transition (EMT) plasticity are promoted by the binding of L2 with RNF20/40, a ubiquitin ligase complex and a strong tumor suppressor [122]. HPV infection also triggers inflammatory pathways, primarily targeting the central regulators of inflammation, the NF-κB, STAT3, and cyclooxygenase-prostaglandin (COX–PG) pathways. In oral cancer, HPV E6 activates the NF-κB pathway by interaction with p50, NF-kappa-B-inducing kinase (NIK), and TRAF-interacting protein; in parallel, E7 inhibits apoptosis by targeting TNF-α [123]. In cervical cancer, the HPV E6-mediated elevated activity of IL-17 and increased expression of IL-1β by HPV E7 activate NF-kB [124]. Moreover, the stimulation of NF-κB by E6 induces the production of IL-6, which is required for the activation of STAT3 [125]. Although persistent HPV infection elevates inflammatory cytokines, IL-6, IL-8, TNF-α and MIP-1α, cervical cancer patients have been shown to display a decrease in lymphoproliferation against HPV infection [126]. The upregulated expression of COX-2 and PG-E by HPV E5, E6, and E7 provoke tissue remodelling, cellular proliferation, angiogenesis, and inhibition of apoptosis.

Malignancy and the spreading of tumors can be supported by miRNAs, functioning as cargoes. The transport of miRNA, channeled through the extracellular matrix and body fluid, involves miRNA encapsulation in exosomes, their transporters and mediators of intercellular communication [127–129]. In HPV-infected cells, the continuous expression of E6/E7 oncoproteins boosted intracellular levels of oncomirs and increased their abundance in exosomes. As body fluids are easier to procure than tissues, profile of exosomal miRNAs can be studied as a basis for diagnosis [130].

HPV also seeks aid from glandular molecules, such as estrogen, that manifest as cocarcinogens. The expression of E6 and E7, elevated levels of estrogen and expression of estrogen receptor alpha (ERα) [131] stimulate the onset and progression of neoplastic lesions in transgenic mouse models with cervical cancer [132]. Working in synergy, HPV and estrogen increase the expression of
proinflammatory chemokines such as CXCL1 [133]. Estrogen has also been shown to upregulate stromal cell-derived growth factor (SDF-1/CXCL12) [133]. Chemokines, such as CXCL1, are present at elevated levels in ascites in OC, promoting the upregulated expression of EGFR and extracellular signal-regulated kinases MAPK/ERK signaling [134]. However, the expression studies of CXCL1 and estrogen in HPV-positive OC are required to define a relation between estrogen and HPV.

In vitro studies based on the immortalization of OSE cells and OC cell lines with HPV-16 E6/E7 may throw light on OC development. Immortalization has been a crucial step in cell transformation and cancer progression [135]. The transfection of OSE cells with HPV-16 E6/E7 has been shown to introduce genomic instability, telomere dysfunction, resistance to anti-tumor agents and the development of malignant characteristics over time [136–140]. The development of isogenic cell line with HR-HPV E6 showed downregulation of p53, AKT/ERK-independent activation of mTOR signaling pathway, utilization of glutamine metabolism for cellular homeostasis and upregulation of calcium-dependent phospholipase A2, which could be involved with migration of cells [141].

5. Herpesvirus Infection in Ovarian Cancer

Herpesviruses are large DNA viruses with a linear double-stranded DNA genome within an icosahedral capsid. These common pathogens can establish life-long infections and contain oncoproteins, promoting malignant transformation and metastasis. They affect cancer-implicated mechanisms, including tumor-promoting inflammation, immune evasion, and immunosuppression (Figure 2). Very few studies have examined the presence of herpesviruses DNA and proteins in OC tissues and, so far, evidence of CMV and/or EBV infection has been detected [65,71–73]. EBV has been recognized as oncogenic, while CMV has been implicated as an oncomodulator in malignant diseases from different cancer entities. The oncomodulatory properties of CMV may play an important role in ovarian carcinogenesis and disease progression. However, the role of herpesviruses in the development of OC is unknown.

CMV is a widespread opportunistic DNA virus with overall seroprevalence ranging from 40% to 100%, depending on age, socioeconomic status, and geographical location [142]. It has developed mechanisms that allow its survival in latent form in an immunocompetent host, reactivating during immunosuppression. CMV can spread to the upper genital tract and infection is usually persistent, latent, and asymptomatic. Several groups have detected CMV infection in various tumor malignancies, including colorectal cancer [143,144], malignant glioma [145], prostatic neoplasia and carcinoma [146,147], cervix cancer [148], breast cancer [149], and EBV-negative Hodgkin’s lymphoma [150]. CMV DNA and proteins have been commonly detected in OC, including HGSOC, and in benign cystadenomas [65,71–73]. The expression of CMV immediate-early (IE) and late tegument (pp65) proteins in most of the tissue sections from OC cases was found [72,73]. Moreover, these patients also had higher levels of CMV-IgG and IgM than healthy controls. The results show the presence of low amounts of CMV DNA in 50%–75% of tumor tissue samples obtained from women with EOC, while low protein expression or expression at different levels was found in most tissue sections, including those from patients with serous EOC [65,71–73]. In contrast, another study did not support any association between CMV and EOC [74]. It has been recently found that almost two-thirds of EOC patients demonstrated coinfection with both CMV and HPV16 in the pathological samples [71].

CMV is not considered to be oncogenic but, instead, acts an oncomodulator that may infect cancer cells and change the TME [151,152]. The onset of carcinogenesis begins with the CMV proteins IE1, IE2, pp71, and pUL97 phosphorylating pRB, inhibiting the cell cycle arrest functions of p53 and interfering with the cyclins, Wnt, PI3K/Akt, NF-κB, and STAT3 [153–155]. CMV proteins inhibit apoptosis and cell cycle arrest and promotes cell proliferation, angiogenesis, inflammation, and immune evasion [156–161]. CMV induces the expression of COX-2, NF-κB, and STAT-3, and the production of proinflammatory cytokines, prostaglandins, and leukotriens [156]. Moreover, translocated NF-κB interacts with the viral immediate early proteins (IE1-72, IE2-55, and IE2-86), transactivates promoters of NF-κB subunits, p105/p50, and p65, thereby elevating its activity [157,158]. For persistent infection, CMV evades immune recognition, downregulates MHC class I and
II markers, and releases cmvIL-10, which impairs maturation of DC and stimulation of cytotoxic T-cells [153,157]. CMV infection in the endothelial cells of blood vessels induces the expression of the adhesion molecules ICAM and VCAM, which enhances monocyte trafficking and secretion of VEGF, a potent angiogenic factor. The interaction of CMV US28 with NF-κB elevates COX2, VEGF, and the migration of macrophages for promoting angiogenesis [158]. CMV strains have been shown to be capable of initiating oncogenesis in human breast epithelial cells by dysregulating p53, pRB, and telomerase [160]. CMV can activate epithelial cells, promote EMT and reverse the process (i.e., mesenchymal to epithelial transition) in tumor cells [160,161]. These CMV-promoted processes may potentially enhance metastatic tumor dissemination through the blood and lymphatic vessels and tumor growth [161]. A key factor for the reactivation of latent CMV is the inflammatory environment. It has been suggested that the inflammatory cytokine IL-6 increases IE expression, cell transition into late-stage gene expression, and the infectivity of the virions produced from latently infected cells [162,163]. Under the influence of IL-3, IL-4, IL-6, M-CSF and G-CSF, infected monocytes harboring latent CMV differentiate into macrophages and dendritic cells and simultaneously reactivate CMV production [163]. IL-6 expression is increased through NF-κB pathway activated by CMV US28 feedback loop. NF-κB-mediated activation of STAT3 and subsequent IL-6 and VEGF expression establish a proliferative signaling, primarily governed by US28 [164]. There is a possibility that the presence of CMV in OC specimens may be a result of the inflammation-induced reactivation of the virus.

EBV is a herpesvirus which infects over 90% of the world’s population before adolescence and which has been associated with human malignancies of epithelial, hematolymphoid, and mesenchymal derivation [165]. It has been associated with nasopharyngeal carcinoma, Burkitt’s

---

**Figure 2.** Signaling pathways deregulated during cytomegalovirus (CMV) infection. CMV may function as an oncomodulator to drive carcinogenesis. It seems to regulate the expression of proteins participating in cell proliferation, cell cycle arrest, cellular metabolism, apoptosis, angiogenesis, inflammation, immune suppression, and EMT plasticity [153–161]. It also codes for proteins that function as homologs for human proteins (such as chemokine receptors, Fc receptors, inhibitor of apoptosis).
lymphoma, and Hodgkin’s lymphoma. EBV appears to play a direct oncogenic role through genome-wide alteration of promoter methylation and expression of miRNA and genes involved in cell motility and transformation pathways [165,166]. EBV DNA has been detected in approximately 5%–7% of EOC tissue samples [74,76], while no DNA virus transcripts were detected in ovarian serous cystadenocarcinoma [75]. Moreover, no association between EOC and EBV antibody levels has been found [167]. It has been suggested that primary EBV infection at a later age may play a role in the etiology of ovarian cancer. An EBV viral miRNA, miR-BART7, induces cisplatin resistance and develops resistance to first-line chemotherapy and early death in patients with serous OC [76]. EBV nuclear antigens (EBNAs) and membrane proteins (LMP1, LMP2A, and LMP2B) are known target the p53 family in lymphomas and nasopharyngeal and gastric cancer [168]. However, the association between EBV and p53 isoforms in OC is yet to be defined.

A low prevalence does not exclude the viral initiation or promotion of tumorigenesis, as described by the “hit and run” hypothesis. It proposes that viruses initiating disease can be lost entirely, obscuring a cancer’s viral origin. The “epigenetic signature” left by a tumor virus on the host cell epigenome may help to identify viral “hit and run” oncogenic events, even after the complete loss of tumor virus genomes from neoplastic cells [86]. The virus-specific epigenetic signatures are the molecular memory which persists after the loss of the viral genome in neoplastic cells. During the “hit” phase, the expression of the EBV oncoprotein LMP1 upregulates the activation of epigenetic markers such as cellular DNA methyltransferases (DNMTs) 1, 3a, and 3b, leading to the hypermethylation of E-cadherin [86]. The upregulation of DNMTs and neoplastic transformation under such epigenetic dysregulation may contribute to the EBV-mediated “hit and run” hypothesis. The study of the epigenetic markers and the copy number of the viral genome in the ovarian tumor and non-cancerous tissues’ surroundings may shed some light on the potential role of viruses in OC.

6. Conclusions

The ovary and its neighboring parts in the female genitalia are highly susceptible to pathogenic infection. We aim to shed light on viral infections that were detected in ovarian tissues and may hold potential in the process of carcinogenesis. However, the role of viruses in the initiation, promotion, and progression of OC is unknown. The oncomodulatory and tumor-promoting inflammatory mechanisms that these viruses instigate may largely promote the development of a long-term, asymptomatic cancer. The detection of viral sequences does not prove pathogenicity as viral sequences are commonly detected in non-malignant tissues. There is a possibility that the TME provides a favorable milieu for the survival of viruses. In addition, viruses interact with the host’s innate immunity, immune sensors, and tumor signaling that control both viral infection and cancer. The identification of markers that favor the survival of the virus and the downstream molecules affected by the virus may help to elucidate the pathogenicity of the virus. The exploration of the causation of the virus–host interactions may lead to additional strategies for prevention and treatment.

If the HPV and/or herpesviruses are drivers of OC pathogenesis, the natural question appears: what therapeutic strategies could be used to manage OC patients? So far, vaccination with DCs pulsed with modified or unchanged tumor-associated antigens (TAAs) has been tested in plenty of immunotherapy trials devoted to advanced OC; however, this has had hardly satisfactory results [169,170]. Another approach to the treatment of patients with OC is based on the vaccination with both long and short peptides (e.g., p53, Her-2/Neu, and NY-ESO-1 or survivin, WT1, and Ca125, respectively) or, alternatively, with carbohydrate epitopes (e.g., GM2, Globo-H, Levis y, sialyl-Tn, and Thompson Friedreich antigen) conjugated to the carrier protein KLH [171]. In many trials, vaccination with recombined viruses has been tested; however, the use of viruses was limited to the role of vectors for TAAs, such as CEA or MUC1. Some initial preclinical trials performed on mice revealed that empty viral capsids of Cowpea mosaic virus (eCPMV VLPs) used for inhalation reduced the formation of metastatic melanoma tumors in lungs, as well as inhibiting metastatic breast, colon, and ovarian cancer [172]. Some researchers have recommended HPV vaccination to reduce the risk of OC [67], but clinical trials using HPV for vaccination against OC are lacking. The
knowledge that a subpopulation of OC expresses non-human genes originating from viruses could be used for designing targeted therapies. They could be designed as either immunotherapies, augmented with viral antigens to treat advanced OC, or as vaccinations, used for the prevention of a subpopulation of OC. CMV-specific immunotherapy (pp65 DC vaccination) and anti-CMV treatment with valganciclovir have shown promise for glioblastoma patients, and these strategies are currently being evaluated in clinical randomized trials [173,174]. The assessment of the efficacy of these vaccines and immune checkpoint inhibitors for OC patients may beget promising preventative measures against OC [175].

**Author Contributions:** E.P. and S.P. designed the review, performed the literature search, and wrote the paper. J.R.W. revised the manuscript critically. S.P., E.P., and J.R.W. finally approved the article. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Statutory Fund of the Institute of Medical Biology of the Polish Academy of Sciences.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Global Cancer Observatory. Available online: https://gco.iarc.fr/ (accessed on 17 June 2019).
2. Bast, R.C.; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: New opportunities for translation. Nat. Rev. Cancer 2009, 9, 415–428.
3. Kurman, R.J.; Visvanathan, K.; Roden, R.; Wu, T.; Shih, I.-M. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 2008, 198, 351–356.
4. Rasmussen, C.B.; Jensen, A.; Albieri, V.; Andersen, K.K.; Kjaer, S.K. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol. Biomark. Prev. 2016, 26, 104–109.
5. Elzek, M.A.; Rodland, K.D. Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev. 2015, 34, 83–96.
6. Spreamico, A.; Oza, A.; Clarke, B.; Mackay, H.; Shaw, P.; Butler, M.; Dhani, N.; Lheureux, S.; Wilson, M.; Welch, S.; et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol. Oncol. 2017, 144, 250–255.
7. Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118, 3030–3044.
8. Biological Agents. Available online: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Biological-Agents-2012 (accessed on 19 July 2019).
9. Butel, J.S. Viral carcinogenesis: Revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000, 21, 405–426.
10. Matulonis, U.A.; Sood, A.K.; Fallowfield, L.; Howitt, B.E.; Sehouli, J.; Karlan, B.Y. Ovarian cancer. Nat. Rev. Dis. Primers 2016, 2, 1–22.
11. Kurman, R. WHO Classification of Tumours of Female Reproductive Organs; Internat Agency for Research on Cancer: Lyon, France, 2014.
12. Lisio, M.-A.; Fu, L.; Goyeneche, A.; Gao, Z.-H.; Telleria, C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 2019, 20, 952.
13. Kurman, R.J.; Shih, I.-M. The dualistic model of ovarian carcinogenesis. Am. J. Pathol. 2016, 186, 733–747.
14. Salazar, C.; Campbell, I.G.; Gorringe, K.L. When is “Type I” ovarian cancer not “Type I”? Indications of an out-dated dichotomy. Front. Oncol. 2018, 8, 1–8.
15. Piek, J.M.; Diest, P.J.V.; Verheijen, R.H.M. Ovarian carcinogenesis: An alternative hypothesis. Adv. Exp. Med. Biol. 2008, 622, 79–87.
16. Yang-Hartwich, Y.; Gurrea-Soteras, M.; Sumi, N.; Joo, W.D.; Holmberg, J.C.; Craveiro, V.; Alvero, A.B.; Mor, G. Ovulation and extra-ovarian origin of ovarian cancer. Sci. Rep. 2014, 4, 6116.
17. Kim, J.; Coffey, D.M.; Creighton, C.J.; Yu, Z.; Hawkins, S.M.; Matzuk, M.M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. USA 2012, 109, 3921–3926.
Cancers 2020, 12, 561

18. Medeiros, F.; Muto, M.G.; Lee, Y.; Elvin, J.A.; Callahan, M.J.; Feltmate, C.; Garber, J.E.; Cramer, D.W.; Crum, C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am. J. Surg. Pathol.* **2006**, *30*, 230–236.

19. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.; et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *J. Pathol.* **2006**, *211*, 26–35.

20. Ahmed, A.A.; Etemadmoghadam, D.; Temple, J.; Lynch, A.G.; Riad, M.; Sharma, R.; Stewart, C.; Fereday, S.; Caldas, C.; Defazio, A.; et al. Driver mutations in tp53 are ubiquitous in high grade serous carcinoma of the ovary. *J. Pathol.* **2010**, *221*, 49–56.

21. Auersperg, N. Ovarian surface epithelium: Biology, endocrinology, and pathology. *Endocr. Rev.* **2001**, *22*, 255–288.

22. Xu, J.; Zheng, T.; Hong, W.; Ye, H.; Hu, C.; Zheng, Y. Mechanism for the decision of ovarian surface epithelial stem cells to undergo neo-oogenesis or ovarian tumorigenesis. *Cell. Physiol. Biochem.* **2018**, *50*, 214–232.

23. Ness, R.B.; Cottreau, C. Possible role of ovarian epithelial inflammation in ovarian cancer. *J. Natl. Cancer Inst.* **1999**, *91*, 1459–1467.

24. Werness, B.A.; Affify, A.M.; Eltabbakh, G.H.; Huelsman, K.; Piver, M.S.; Paterson, J.M. p53, c-ErbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. *Int. J. Gynecol. Pathol.* **1999**, *18*, 338–343.

25. Banet, N.; Kurman, R. Two types of ovarian cortical inclusion cysts. *Int. J. Gynecol. Pathol.* **2015**, *34*, 3–8.

26. Togami, S.; Sasajima, Y.; Kasamatsu, T.; Oda-Otomo, R.; Okada, S.; Ishikawa, M.; Ikeda, S.-I.; Kato, T.; Tsuda, H. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix. *Pathol. Oncol. Res.* **2014**, *21*, 487–494.

27. Mungenast, F.; Thalhammer, T. Estrogen biosynthesis and action in ovarian cancer. *Front. Endocrinol.* **2014**, *5*, 1–12.

28. Syed, V.; Zhang, X.; Lau, K.-M.; Cheng, R.; Mukherjee, K.; Ho, S.-M. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. *Oncogene* **2005**, *24*, 8128–8143.

29. Simpkins, F.; Garcia-Soto, A.; Slingerland, J. New insights on the role of hormonal therapy in ovarian cancer. *Steroids* **2013**, *78*, 530–537.

30. Morrison, J.; Thoma, C.; Goodall, R.J.; Lyons, T.J.; Gaitskell, K.; Wiggans, A.J.; Bryant, A. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. *Cochrane Database Syst. Rev.* **2018**, *10*, 1–100.

31. Ingerslev, K.; Høgdall, E.; Schnack, T.H.; Skovrider-Ruminski, W.; Høgdall, C.; Blaakaer, J. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. *Infect. Agents Cancer* **2017**, *12*, 1–10.

32. Savant, S; Sriramkumar, S.; O’Hagan, H. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. *Cancers* **2018**, *10*, 251.

33. Jia, D.; Nagaoka, Y.; Katsumata, M.; Orsulic, S. Inflammation is a key contributor to ovarian cancer cell seeding. *Sci. Rep.* **2018**, *8*, 1–7.

34. Clendenen, T.V.; Lundin, E.; Zeleniuch-Jacquotte, A.; Koenig, K.L.; Berrino, F.; Lukanova, A.; Lokshin, A.E.; Idahl, A.; Ohlson, N.; Hallmans, G.; et al. Circulating inflammation markers and risk of epithelial ovarian cancer. *Cancer Epidemiol. Biomark. Prev.* **2011**, *20*, 799–810.

35. Dobrzychka, B.; Terlikowski, S.J.; Kowalczyk, O.; Kinalska, M. Circulating levels of TNF-α and its soluble receptors in the plasma of patients with epithelial ovarian cancer. *Eur. Cytokine Netw.* **2009**, *20*, 131–134.

36. Thibault, B.; Castells, M.; Delord, J.P.; Couderc, B. Ovarian cancer microenvironment: Implications for cancer dissemination and chemoresistance acquisition. *Cancer Metast. Rev.* **2013**, *33*, 17–39.

37. Sapoznik, S.; Bahar-Shany, K.; Brand, H.; Pinto, Y.; Gabay, O.; Glick-Saar, E.; Dor, C.; Zadok, O.; Barshack, I.; Zundelevich, A.; et al. Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis. *Neoplasia* **2016**, *18*, 90–99.

38. Nola, R.D.; Menga, A.; Castegna, A.; Loizzi, V.; Ranieri, G.; Cinelli, E.; Cormio, G. The crowded crosstalk between cancer cells and stromal microenvironment in gynecological malignancies: Biological pathways and therapeutic implication. *Int. J. Mol. Sci.* **2019**, *20*, 1–29.
39. Mia, S.; Warnecke, A.; Zhang, X.M.; Malmström, V.; Harris, R.A. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-β yields a dominant immunosuppressive phenotype. *Scand. J. Immunol.* **2014**, *79*, 305–314.

40. Webb, J.R.; Milne, K.; Kroeger, D.R.; Nelson, B.H. PD-L1 expression is associated with tumor-infiltrating T-cells and favorable prognosis in high-grade serous ovarian cancer. *Gynecol. Oncol.* **2016**, *141*, 293–302.

41. Liang, L.; Jiang, Y.; Chen, J.-S.; Niu, N.; Piao, J.; Ning, J.; Zu, Y.; Zhang, J.; Liu, J. B7-H4 expression in ovarian serous carcinoma: A study of 306 cases. *Hum. Pathol.* **2016**, *57*, 1–6.

42. Liu, Z.; Shimada, M.; Richards, J.S. The involvement of the toll-like receptor family in ovulation. *J. Assist. Reprod. Genet.* **2008**, *25*, 223–228.

43. Zhou, M.; Mcfarland-Mancini, M.M.; Funk, H.M.; Husseinazadeh, N.; Mounajeed, T.; Drew, A.F. Toll-like receptor expression in normal ovary and ovarian tumors. *Cancer Immunol. Immunother.* **2009**, *58*, 1375–1385.

44. Berger, R.; Fiegls, H.; Goebel, G.; Obserex, P.; Asserlechner, M.; Doppler, W.; Hauser-Kronberger, C.; Reitsamer, R.; Egle, D.; Reimer, D.; et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. *Cancer Sci.* **2010**, *101*, 1059–1066.

45. Hasan, U.A.; Zannetti, C.; Parroche, P.; Goutagny, N.; Malfroy, M.; Roblot, G.; Carreira, C.; Hussain, I.; Müller, M.; Taylor-Papadimitriou, J.; et al. The Human Papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. *J. Exp. Med.* **2013**, *210*, 1369–1387.

46. Reiser, J.; Hurst, J.; Voges, M.; Krauss, P.; Munch, P.; Iftner, T.; Stubenrauch, F. High-Risk Human Papillomavirusviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. *J. Virol.* **2011**, *85*, 11372–11380.

47. Zhou, B.; Sun, C.; Huang, J.; Xia, M.; Guo, E.; Li, N.; Lu, H.; Shan, W.; Wu, Y.; Li, Y.; et al. The biodiversity composition of microbiome in ovarian carcinoma patients. *Sci. Rep.* **2019**, *9*, 1691.

48. Bougherara, H.; Mansuet-Lupo, A.; Alifano, M.; Ngö, C.; Damotte, D.; Le Frère-Belda, M.A.; Donnadieu, E.; Peranzoni, E. Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. *Front. Immunol.* **2015**, *6*, 500.

49. Nielsen, J.S.; Nelson, B.H. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. *Oncoimmunology* **2012**, *1*, 1623–1625.

50. Fialová, A.; Partlová, S.; Sojka, L.; Hromádková, H.; Brtnický, T.; Fučíková, J.; Kocián, P.; Rob, L.; Bartuňková, J.; Špišek, R. Dynamics of T-Cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. *Int. J. Cancer* **2012**, *132*, 1070–1079.

51. Santoemma, P.P.; Powell, D.J., Jr. Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biol. Ther.* **2015**, *16*, 807–820.

52. Zhou, J.; Li, X.; Wu, X.; Zhang, T.; Zhu, Q.; Wang, X.; Wang, X.; Wang, K.; Lin, Y.; Wang, X. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/th17 cell imbalance in epithelial ovarian cancer. *Cancer Immunol. Res.* **2018**, *6*, 1578–1592.

53. Chiang, C.L.; Kandalat, L.E.; Tanyi, J.; Hagemann, A.R.; Motz, G.T.; Svoronos, N.; Montone, K.; Manta-Smaldone, G.M.; Smith, L.; Nisenbaum, H.L.; et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside. *Clin. Cancer Res.* **2013**, *19*, 4801–4815.

54. Alibek, K.; Karatayeva, N.; Bekniyazov, I. The role of infectious agents in urogenital cancers. *Infect. Agents Cancer* **2012**, *7*, 1–7.

55. Silva, J.; Cerqueira, F.; Medeiros, R. *Chlamydia trachomatis* infection: Implications for HPV status and cervical cancer. *Arch. Gynecol. Obstet.* **2014**, *289*, 715–723.

56. Banerjee, S.; Tian, T.; Wei, Z.; Shih, N.; Feldman, M.D.; Coukos, G.; Alwine, J.C.; Robertson, E.S. The ovarian cancer oncoimmunity. *Oncotarget* **2015**, *8*, 36225–36245.

57. Leake, J.; Woodruff, J.; Searle, C.; Shah, K.; Currie, J. Human Papillomavirus and epithelial ovarian neoplasia. *Gynecol. Oncol.* **1989**, *32*, 268–273.

58. Lai, C.-H.; Hsueh, S.; Lin, C.-Y.; Huang, M.-Y.; You, G.-B.; Chang, H.-C.; Pao, C.C. Human Papillomavirus in benign and malignant ovarian and endometrial tissues. *Int. J. Gynecol. Pathol.* **1992**, *11*, 210–215.

59. Runnebaum, I.B.; Maier, S.; Tong, X.W.; Rosenthal, H.E.; Möbus, V.J.; Kieback, D.G.; Kreienberg, R. Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients. *Cancer Epidemiol. Biomark. Prev.* **1995**, *4*, 573–575.
60. Anttila, M.; Syrjänen, S.; Ji, H.; Saarikoski, S.; Syrjänen, K. Failure to demonstrate Human Papillomavirus DNA in epithelial ovarian cancer by general primer PCR. *Gynecol. Oncol.* 1999, 72, 337–341.

61. Wu, Q.-J.; Guo, M.; Lu, Z.-M.; Li, T.; Qiao, H.-Z.; Ke, Y. Detection of Human Papillomavirus-16 in ovarian malignancy. *Br. J. Cancer* 2003, 89, 672–675.

62. Kuscu, E.; Ozdemir, B.H.; Erkanli, S.; Haberal, A. HPV and p53 expression in epithelial ovarian carcinoma. *Eur. J. Gynaecol. Oncol.* 2005, 10, 642–645.

63. Atalay, F.; Taskiran, C.; Taner, M.Z.; Pak, I.; Or, M.; Tuncer, S. Detection of Human Papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. *J. Obstet. Gynaecol. Res.* 2007, 33, 823–828.

64. Giordano, G.; Dadda, T.; Gernet, L.; Froio, E.; Merisio, C.; Melpignano, M. Role of Human Papillomavirus in the development of epithelial ovarian neoplasms in Italian women. *J. Obstet. Gynaecol. Res.* 2008, 34, 210–217.

65. Shanmughapriya, S.; Senthilkumar, G.; Vinodhini, K.; Das, B.C.; Vasanthi, N.; Natarajaseenivasan, K. Viral and bacterial aetiologies of epithelial ovarian cancer. *Eur. J. Clin. Microbiol. Infect. Dis.* 2012, 31, 2311–2317.

66. Malisic, E.; Jankovic, R.; Jakovljevic, K. Detection and genotyping of Human Papillomaviruses and their role in the development of ovarian carcinomas. *Arch. Gynecol. Obstet.* 2012, 286, 723–728.

67. Al-Shabanah, O.A.; Hafez, M.M.; Hassan, Z.K.; Sayed-Ahmed, M.M.; Abozeed, W.N.; Al-Rejaie, S.S.; Alsheikh, A.A. Human Papillomavirus genotyping and integration in ovarian cancer Saudi patients. *Virol. J.* 2013, 10, 1–9.

68. Bilyk, O.O.; Pande, N.T.; Pejovic, T.; Buchynska, L.G. The frequency of Human Papillomavirus types 16, 18 in upper genital tract of women at high risk of developing ovarian cancer. *Exp. Oncol.* 2014, 36, 121–124.

69. Ingerslev, K.; Högdall, E.; Skovrider-Ruminski, W.; Schnack, T.H.; Karlson, M.A.; Nedergaard, L.; Högdall, C.; Blaakaer, J. High-Risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. *Infect. Agents Cancer* 2016, 11, 1–6.

70. Hassan, Z.K.; Hafez, M.M.; Kamel, M.M.; Zekri, A.R. Human papillomavirus genotypes and methylation of CADMI, PAX1, MAL and ADCYAP1 genes in epithelial ovarian cancer patients. *Asian Pac. J. Cancer* 2017, 18, 169–176.

71. Paradowska, E.; Jabłońska, A.; Studzińska, M.; Wilczyński, M.; Wilczyński, J.R. Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. *Sci. Rep.* 2019, 9, 19935.

72. Rådestad, A.; Estekizadeh, A.; Cui, H.; Kostopoulou, O.; Davoudi, B.; Hirschberg, A.; Carlson, J.; Rahbar, A.; Söderberg-Naucler, C. Impact of human cytomegalovirus infection and its immune response on survival of patients with ovarian cancer. *Transl. Oncol.* 2018, 11, 1292–1300.

73. Carlson, J.; Rådestad, A.; Söderberg-Naucler, C.; Rahbar, A. Human Cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival. *Medicine* 2018, 97, 1–5.

74. Ingerslev, K.; Högdall, E.; Skovrider-Ruminski, W.; Schnack, T.H.; Lidang, M.; Högdall, C.; Blaakaer, J. The prevalence of EBV and CMV DNA in epithelial ovarian cancer. *Infect. Agents Cancer* 2019, 14, 1–6.

75. Khoury, J.; Tannir, N.; Williams, M.; Chen, Y.; Yao, H.; Zhang, J.; Thompson, E.; Meric-Bernstam, F.; Medeiros, L.; Weinstein, J.; Su, X. Landscape of DNA virus associations across human malignant cancers: Analysis of 3,775 cases using RNA-Seq. *J. Virol.* 2013, 87, 8916–8926.

76. Pandya, D.; Mariani, M.; McHugh, M.; Andreoli, M.; Sieber, S.; He, S.; Dowell-Martino, C.; Fiedler, P.; Scambia, G.; Ferlini, C. Herpes virus microRNA expression and significance in serous ovarian cancer. *PLoS ONE* 2014, 12, e114750.

77. McQuillan, G.M.; Kruzson-Moran, D.; Markowitz, L.E.; Unger, E.R.; Paulose-Ram, R. *Prevalence of HPV in Adults Aged 18–69: United States, 2011–2014*; US Department of Health and Human Services, Centers for Disease Control and Prevention, Ed.; National Center for Health Statistics: Hyattsville, MD, USA, 2017; pp. 1–8.

78. Zhao, F.H.; Lewkowitz, A.K.; Hu, S.Y.; Chen, F.; Li, L.Y.; Zhang, Q.M.; Wu, R.F.; Li, C.Q.; Wei, L.H.; Xu, A.D.; et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population-based studies. *Int. J. Cancer* 2012, 131, 2929–2938.

79. Tang, K.-W.; Alaei-Mahabadi, B.; Samuelsson, T.; Lindh, M.; Larsson, E. The landscape of viral expression and host gene fusion and adaptation in human cancer. *Nat. Commun.* 2013, 4, 2513.

80. Svanh, M.F.; Faber, M.T.; Christensen, J.; Norrild, B.; Kjaer, S.K. Prevalence of Human Papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. *Acta Obstet. Gynecol. Scand.* 2013, 93, 6–19.
101. Ozbun, M.A. Human Papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. *J. Virol.* **2002**, *76*, 11291–11300.

102. Bernard, X.; Robinson, P.; Nomine, Y.; Masson, M.; Charbonnier, S.; Ramirez-Ramos, J.R.; Deryckere, F.; Travé, G.; Orfanoudakis, G. Proteosomal degradation of p53 by Human Papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. *PLoS ONE* **2011**, *6*, e25981.

103. McLaughlin-Drubin, M.E.; Münger, K. The Human Papillomavirus E7 oncoprotein. *Virology* **2009**, *384*, 335–344.

104. Cinatl, J.; Scholz, M.; Kotchetkov, R.; Vogel, J.-U.; Doerr, H.W. Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. *Trends Mol. Med.* **2004**, *10*, 19–23.

105. Söderberg-Naucler, C. Cytomegalovirus in human brain tumors: role in pathogenesis and potential treatment options. *World J. Exp. Med.* **2015**, *5*, 1–10.

106. Niller, H.H.; Wolf, H.; Minarovits, J. Viral hit and run-oncogenesis: genetic and epigenetic scenarios. *Cancer Lett.* **2011**, *305*, 200–217.

107. Emara, M.; Vyas, V.; el Awadi, S.; Jaroslav, N.; Khodry, A.; Essam, T.; Rouf, Y.; Amanguno, H.; Purohit, P. Synchronous occurrence of brucellosis and ovarian cancer detected using sensitive PCR methods and antiviral therapies. *Future Microbiol.* **2009**, *5*, e1000318.

108. Scidmore, M.A.; Fischer, E.R.; Hackstadt, T. Restricted fusion of *Chlamydia trachomatis* vesicles with endocytic compartments during the initial stages of infection. *Infect. Immun.* **2003**, *71*, 973–984.

109. Zhong, G.; Liu, L.; Fan, T.; Fan, P.; Ji, H. Degradation of transcription factor Rfx5 during the inhibition of both constitutive and interferon γ-inducible major histocompatibility complex class I expression in chlamydia-infected cells. *J. Exp. Med.* **2000**, *191*, 1525–1534.

110. Chumduri, C.; Gurumurthy, R.K.; Zadora, P.K.; Mi, Y.; Meyer, T.F. Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response. *Cell Host Microbe* **2013**, *13*, 746–758.

111. González, E.; Rother, M.; Kerr, M.C.; Al-Zeer, M.A.; Abu-Lubad, M.; Kessler, M.; Brinkmann, V.; Loewer, A.; Meyer, T.F. *Chlamydia* infection depends on a functional MDM2–p53 axis. *Nat. Commun.* **2014**, *5*, 1–10.

112. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. *Cell* **2011**, *144*, 646–674.

113. Chan, P.J.; Seraj, I.M.; Kalugdan, T.H.; King, A. Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR–ELISA. *Gynecol. Oncol.* **1996**, *63*, 258–260.

114. Jones, A.; Jonsson, A.-B.; Aro, H. *Neisseria gonorrhoeae* infection causes a G1 arrest in human epithelial cells. *FASEB J.* **2007**, *21*, 345–355.

115. Idahl, A.; Lundin, E.; Elgh, F.; Jurfstrand, M.; Möller, J.K.; Marklund, I.; Lindgren, P.; Ottander, U. *Chlamydia trachomatis*, *Mycoplasma genitalium*, *Neisseria gonorrhoeae*, Human Papillomavirus, and Polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. *Am. J. Obstet. Gynecol.* **2010**, *202*, 71, 1–6.

116. Human Papillomaviruses. In *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*; IARC: Lyon, France, 2007; Volume 64, pp. 47–79.

117. Graham, S. Human Papillomavirus: Gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. *Future Microbiol.* **2010**, *5*, 1493–1506.

118. Pyeon, D.; Pearce, S.; Lank, S.; Ahlquist, P.; Lambert, P. Establishment of Human Papillomavirus infection requires cell cycle progression. *PLoS Pathog.* **2009**, *5*, e1000318.

119. Langsfeld, E.; Laimins, L.A. Human papillomaviruses: Research priorities for the next decade. *Trends Cancer* **2016**, *2*, 234–240.

120. Hausen, H.Z. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. *J. Natl. Cancer Inst.* **2000**, *92*, 690–698.

121. Kines, R.C.; Cerio, R.J.; Roberts, J.N.; Thompson, C.D.; Pinos, E.D. L.; Lowy, D.R.; Schiller, J.T. Human Papillomavirus capsids preferentially bind and infect tumor cells. *Int. J. Cancer* **2015**, *138*, 901–911.

122. Florin, L.; Becker, K.A.; Lambert, C.; Nowak, T.; Sapp, C.; Strand, D.; Streeck, R.E.; Sapp, M. Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. *J. Virol.* **2006**, *80*, 6691–6696.

123. Petersen, I.; Klein, F. HPV in non-gynecological tumors. *Pathol. Virology* **2008**, *29*, 118–122.
105. Helt, A.-M.; Funk, J.O.; Galloway, D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the Human Papillomavirus Type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. *J. Virol.* **2002**, *76*, 10559–10568.

106. Munger, K.; Baldwin, A.; Edwards, K.M.; Hayakawa, H.; Nguyen, C.L.; Owens, M.; Grace, M.; Huh, K. Mechanisms of Human Papillomavirus-induced oncogenesis. *J. Virol.* **2004**, *78*, 11451–11460.

107. Kiyono, T.; Foster, S.A.; Koop, J.I.; Mcdougall, J.K.; Galloway, D.A.; Klingelhutz, A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. *Nature* **1998**, *396*, 84–88.

108. Woodman, C.B. J.; Collins, S.I.; Young, L.S. The natural history of cervical HPV infection: Unresolved issues. *Nat. Rev. Cancer* **2007**, *7*, 11–22.

109. Hoppe-Seyler, F.; Butz, K. Cellular control of Human Papillomavirus oncogene transcription. *Mol. Carcinog.* **1994**, *10*, 134–141.

110. Tsai, T.-C.; Chen, S.-L. The biochemical and biological functions of Human Papillomavirus Type 16 E5 protein. *Arch. Virol.* **2003**, *148*, 1445–1453.

111. Crusius, K.; Rodriguez, I.; Alonso, A. The Human Papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. *Viruses Genes* **2000**, *20*, 65–69.

112. Zhang, B.; Spandau, D.F.; Roman, A. E5 protein of Human Papillomavirus Type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. *J. Virol.* **2002**, *76*, 220–231.

113. Alloul, N.; Sherman, L. Transcription-modulatory activities of differentially spliced cDNAs encoding the E2 protein of Human Papillomavirus Type 16. *J. Gen. Virol.* **1999**, *80*, 2461–2470.

114. Olmedo-Nieva, L.; Muñoz-Bello, J.; Contreras-Paredes, A.; Lizano, M. The role of E6 spliced isoforms (E6*) in Human Papillomavirus-induced carcinogenesis. *Viruses* **2018**, *10*, 45.

115. Pin, D.; Massimi, P.; Banks, L. Alternatively Spliced HPV-18 E6* Protein Inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. *Oncogene* **1997**, *15*, 257–264.

116. Williams, V.; Filippova, M.; Filipiov, V.; Payne, K.; Duerksen-Hughes, P. Human Papillomavirus Type 16 E6* induces oxidative stress and DNA damage. *J. Virol.* **2014**, *88*, 6751–6761.

117. Ajiro, M.; Zheng, Z. E6^E7, A novel splice isoform protein of Human Papilloma virus 16, stabilizes viral E6 And E7 oncoproteins via HSP90 and GRP78. *mBio* **2015**, *6*, 1–15.

118. Roos, P.; Orlando, P.; Fagerstrom, R.; Pepper, J. In North America, some ovarian cancers express the oncogenes of preventable Human Papillomavirus HPV-18. *Sci. Rep.* **2015**, *5*, 8645.

119. Bilyk, O.O.; Pande, N.T.; Buchynska, L.G. Analysis of p53, p16^ink4a, pRB and cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. *Exp. Oncol.* **2011**, *33*, 150–156.

120. Arfi, A.; Hequet, D.; Bataillon, G.; Tran-Perennou, C.; Farkhondeh, F.; Sastre-Garau, X.; Fourchotte, V.; Rouzier, R.; Laas, E.; Pouget, N.; Vincent-Salomon, A.; Jeannot, E. HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: Three case reports. *BMC Cancer* **2019**, *19*, 1–6.

121. Al-Shabanah, O.; Hafez, M.; Hassan, Z.; Sayed-Ahmed, M.; Abozeed, W.; Alsheikh, A.; Al-Rejaie, S. Methylation of Sfrps and APC genes in ovarian cancer infected with high risk Human Papillomavirus. *Asian Pac. J. Cancer* **2014**, *15*, 2719–2725.

122. Eckhardt, M.; Zhang, W.; Gross, A.; Von Dollen, J.; Johnson, J.; Franks-Skiba, K.; Swaney, D.; Johnson, T.; Jang, G.; Shah, P.; et al. Multiple routes to oncogenesis are promoted by the Human Papillomavirus-host protein network. *Cancer Discov.* **2018**, *8*, 1474–1489.

123. Brücher, B.L.; Lang, F.; Jamall, I.S. NF-xB signaling and crosstalk during carcinogenesis. *4Open* **2019**, *2*, 1–35.

124. Hemmat, N.; Bannazadeh-Bagheri, H. Association of human papillomavirus infection and inflammation in cervical cancer. *Pathog. Dis.* **2019**, *77*, 1–36.

125. Morgan, E.L.; Macdonald, A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFxB-IL-6 signalling axis. *PLoS Pathog.* **2019**, *15*, e1007835.
127. Olive, V.; Li, Q.; He, L. Mir-17-92: A polycistronic oncomir with pleiotropic functions. *Immunol. Rev.* **2013**, *253*, 158–166.

128. Honegger, A.; Schilling, D.; Bastian, S.; Sponagel, J.; Kuryshhev, V.; Sültmann, H.; Scheffner, M.; Hoppe-Seyler, K.; Hoppe-Seyler, F. Dependence of intracellular and exosomal micronas on viral E6/E7 oncogene expression in HPV-positive tumor cells. *PLoS Pathog.* **2015**, *11*, e1004712.

129. Valadi, H.; Ekström, K.; Bossios, A.; Sjöström, M.; Lee, J.; Lötving, J. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **2007**, *9*, 654–659.

130. Spurgeon, M.; den Boon, J.; Horswill, M.; Barthakur, S.; Forouzan, O.; Rader, J.; Beebe, D.; Roopra, A.; Ahlquist, P.; Lambert, P. Human Papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 9076–9085.

131. Chung, S.; Wiedmeyer, K.; Shai, A.; Korach, K.; Lambert, P. Requirement for estrogen receptor in a mouse model for Human Papillomavirus-associated cervical cancer. *Cancer Res.* **2008**, *68*, 9928–9934.

132. Brake, T.; Lambert, P. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a Human Papillomavirus-transgenic mouse model. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 2490–2495.

133. Glace, L.; Grygielko, E.; Boyle, R.; Wang, Q.; Laping, N.; Sulpizio, A.; Bray, J. Estrogen-induced Stromal cell-Derived Factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by selective estrogen receptor modulators via estrogen receptor alpha in rat uterine cells and tissues. *Steroids* **2009**, *74*, 1015–1024.

134. Bolitho, C.; Hahn, M.; Baxter, R.; Marsh, D. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. *Endocr. Relat. Cancer* **2010**, *17*, 929–940.

135. Hahn, W.C. Immortalization and transformation of human cells. *Mol. Cells* **2002**, *13*, 351–361.

136. Jin, Y.; Zhang, H.; Tsao, S.W.; Jin, C.; Lv, M.; Strömbeck, B.; Wiegant, J.; Wan, T.S.; Yuen, P.W.; Kwong, Y.L. Cytogenetic and molecular genetic characterization of immortalized human ovarian surface epithelial cell lines: consistent loss of chromosome 13 and amplification of chromosome 20. *Gynecol. Oncol.* **2004**, *92*, 183–191.

137. Tsao, S.W.; Wong, N.; Wang, X.; Liu, Y.; Wan, T.S.; Fung, L.F.; Lancaster, W.D.; Gregoire, L.; Wong, Y.C. Nonrandom chromosomal imbalances in human ovarian surface epithelial cells immortalized by HPV16-E6/E7 viral oncogenes. *Cancer Genet. Cytogenet.* **2001**, *130*, 141–149.

138. Gisselsson, D.; Lv, M.; Tsao, S.W.; Man, C.; Jin, C.; Höglund, M.; Kwong, Y.L.; Jin, Y. Telomere-mediated mitotic disturbances in immortalized ovarian epithelial cells reproduce chromosomal losses and breakpoints from ovarian carcinoma. *Genes Chromosomes Cancer* **2005**, *42*, 22–33.

139. Chung, C.M.; Man, C.; Jin, Y.; Jin, C.; Guan, X.Y.; Wang, Q.; Wan, T.S.; Cheung, A.L.; Tsao, S.W. Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. *Mol. Carcinog.* **2005**, *43*, 165–174.

140. Gregoire, L.; Rabah, R.; Schmelz, E.M.; Munkarah, A.; Roberts, P.C.; Lancaster, W.D. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. *Clin. Cancer Res.* **2001**, *7*, 4280–4287.

141. Chung, Y.; Nagy, E.; Zietkowskii, D.; Payne, G.; Phillips, D.; deSouza, N. Molecular and metabolic consequences following E6 transfection in an isogenic ovarian cell line (A2780) pair. *Cell. Physiol. Biochem.* **2013**, *32*, 1460–1472.

142. Cannon, M.; Schmid, D.; Hyde, T. Review of Cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev. Med. Virol.* **2010**, *20*, 202–213.

143. Harkins, L.; Volk, A.; Samanta, M.; Mikolaenko, I.; Britt, W.; Bland, K.; Cobbs, C. Specific localisation of Human Cytomegalovirus nucleic acids and proteins in human colorectal cancer. *Lancet* **2002**, *360*, 1557–1563.

144. Chen, H.; Jiang, J.; Chen, C.; Chou, T.; Chen, Y.; Chang, Y.; Lin, S.; Chan, C.; Yang, C.; Lin, C.; et al. Human Cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis. *J. Clin. Virol.* **2012**, *54*, 240–244.

145. Cobbs, C.S.; Harkins, L.; Samanta, M.; Gillespie, G.Y.; Bharara, S.; King, P.H.; Nabors, L.B.; Cobbs, C.G.; Brit, W.J. Human Cytomegalovirus infection and expression in human malignant glioma. *Cancer Res.* **2002**, *62*, 3347–3350.
146. Sanford, E.; Geder, L.; Laychock, A.; Rohner, T.; Rapp, F. Evidence For the association of Cytomegalovirus with carcinoma of the prostate. *J. Urol.* 1977, **118**, 789–792.

147. Samanta, M.; Harkins, L.; Klemm, K.; Brit, W.; Cobbs, C. High prevalence of Human Cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. *J. Urol.* 2003, **170**, 998–1002.

148. Pacsa, A.; Kummerländer, L.; Pejtsik, B.; Pali, K. Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls. *J. Natl. Cancer Inst.* 1975, **55**, 775–781.

149. Harkins, L.; Matlaf, L.; Soroceanu, L.; Klemm, K.; Brit, W.; Wang, W.; Bland, K.; Cobbs, C. Detection of Human Cytomegalovirus in normal and neoplastic breast epithelium. *Herpesviridae* 2010, **1**, 8.

150. Huang, G.; Yan, Q.; Wang, Z.; Chen, X.; Zhang, X.; Guo, Y.; Li, J. Human Cytomegalovirus in neoplastic cells of Epstein-Barr Virus negative Hodgkin’s disease. *Int. J. Oncol.* 2002, **21**, 31–36.

151. Michaelis, M.; Doerr, H.; Cinatl, J. The story of Human Cytomegalovirus and cancer: Increasing evidence and open questions. *Neoplasia* 2009, **11**, 1–9.

152. Cobbs, C. Cytomegalovirus is a tumor-associated virus: armed and dangerous. *Curr. Opin. Virol.* 2019, **39**, 49–59.

153. Herbein, G. The Human Cytomegalovirus, from oncomodulation to oncogenesis. *Viruses* 2018, **10**, 408.

154. Hume, A.; Finkel, J.; Kamil, J.; Coen, D.; Culbertson, M.; Kalejta, R. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. *Science* 2008, **320**, 797–799.

155. Cinatl, J.; Vogel, J.; Kotchetkov, R.; Wilhelm Doerr, H. Oncomodulatory signals by regulatory proteins encoded by Human Cytomegalovirus: a novel role for viral infection in tumor progression. *FEMS Microbiol. Rev.* 2004, **28**, 59–77.

156. Söderberg-Nauclér, C. Does Cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? *J. Int. Med.* 2006, **259**, 219–246.

157. Caposio, P.; Orloff, S.; Streblow, D. The role of Cytomegalovirus in angiogenesis. *Virus Res.* 2011, **157**, 204–211.

158. Yurochko, A.D.; Kowalk, T.F.; Huang, S.M.; Huang, E.S. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. *J. Virol.* 1995, **69**, 5391–5400.

159. Rodríguez-Sánchez, I.; Munger, J. Meal for two: Human Cytomegalovirus and ERBB2 activity by transactivating the NF kappa-B p105/p50 and its homologs during EBV associated malignancies. *Heliyon* 2019, **5**, e02684.

160. Littman, A.; Rossing, M.; Madeleine, M.; Tang, M.; Yasui, Y. Association between late age at infectious mononucleosis, Epstein-Barr virus antibodies, and ovarian cancer risk. *Scand. J. Infect. Dis.* 2003, **35**, 728–735.

161. Chatterjee, K.; Das, P.; Chattopadhyay, N.R.; Mal, S.; Choudhuri, T. The interplay between Epstein-Barr virus (EBV) with the p53 and its homologs during EBV associated malignancies. *Herpesviruses* 2019, **5**, e02624.

162. Kim, S.; Han, Y.; Kim, S.I.; Kim, H.S.; Kim, S.J.; Song, Y.S. Tumor evolution and chemoresistance in ovarian cancer. *NPJ Precis. Oncol.* 2018, **2**, 1–9.
170. Paijens, S.T.; Leffers, N.; Daemen, T.; Helfrich, W.; Boezen, H.M.; Cohlen, B.J.; Melief, C.J.; de Bruyn, M.; Nijman, H.W. Antigen-specific active immunotherapy for ovarian cancer. *Cochrane Database Syst. Rev.* 2018, 9, CD007287.

171. O’Cearbhaill, R.E.; Ragupathi, G.; Zhu, J.; Wan, Q.; Mironov, S.; Yang, G.; Spassova, M.K.; Iasonos, A.; Kravetz, S.; Ouerfelli, O.; et al. A phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. *Cancers* 2016, 8, E46.

172. Lizotte, P.H.; Wen, A.M.; Sheen, M.R.; Fields, J.; Rojanasopondist, P.; Steinmetz, N.F.; Fiering, S. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. *Nat. Nanotechnol.* 2016, 11, 295–303.

173. Schuessler, A.; Smith, C.; Beagley, L.; Boyle, G.M.; Rehan, S.; Matthews, K.; Jones, L.; Crough, T.; Dasari, V.; Klein, K.; Smalley, A. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. *Cancer Res.* 2014, 74, 3466–3476.

174. Nair, S.K.; Sampson, J.H.; Mitchell, D.A. Immunological targeting of cytomegalovirus for glioblastoma therapy. *Oncovirology* 2014, 3, e29289.

175. Gao, P.; Lazare, C.; Cao, C.; Meng, Y.; Wu, P.; Zhi, W.; Lin, S.; Wei, J.; Huang, X.; Xi, L.; et al. Immune checkpoint inhibitors in the treatment of virus-associated cancers. *J. Hematol. Oncol.* 2019, 12, 58.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).